Quantifying the benefits of genomics is a key focus of the InGeNA Strategic Plan launched today.

InGeNA has commenced a major project with Deloitte Access Economics to develop an evidence base to demonstrate the value of genomics to the economy, society and patient care.

Committed to ensuring a patient-centric approach, removing barriers for patient outcomes, the strategy is also focused on:

  • Access and equity: Advocating for patient equity and access to personalised healthcare.
  • Workforce: Advancing industry skills and development to build a workforce for the age of precision health.
  • Data and technology innovation: Driving the value of genomics information management and national data infrastructure to support advanced care.

The InGeNA Strategic Plan highlights the breadth and range of industry groups committed to working together to bring a shared perspective on critically important areas underpinning the future of genomics.